In November, the CPHI 2022 in Frankfurt, the leading trade fair for the pharmaceutical industry, finally ended our long absence from trade fairs. We were all very excited to finally see our customers, business partners and friends again, resume personal discussions and make new contacts. One topic was especially important to us: Sustainability. And we were particularly proud of an innovation with a great deal of potential.
Finally, the time has come! We will be live at the CPHI Worldwide with a booth. We had to wait until today to present our new trade fair appearance to you and are all the more pleased to welcome you from November 1st to 3rd, 2022 in Frankfurt. Because nothing can replace face-to-face contact.
Topical uses of our specialty products are a pivotal component of our daily aspiration at IOI Oleo GmbH. The business units Pharma and Personal care have common history and share products and expertise to help customers developing high quality, sensorially appealing formulations.
According to a conservative estimate, approximately 1,000,000,000 (1 billion) individual patient doses are manufactured annually with our WITEPSOL® products for the application area of pain and fever management. This not only makes us proud, but also underlines our position as a global benchmark.
In 1843 the Englishman William Brockedon (1787 - 1854) applied for a patent for the tablet and caused “one of the most tremendous upheavals that the pharmacists have ever experienced”. Thereby active ingredients can be precisely dosed and are very stable, the taking is convenient, the production cheap and they are easy to transport. As a result, tablets occupy a special position today with a share of almost 50% among the drug forms.
A trend that we are seeing in the market in the USA is the improvement of patient compliance. "Take 1 tablet instead of having to think about regularly taking 3 tablets a day." A trend that we are seeing in the USA addresses just this topic. The goal is to ensure the release of the active ingredients over a longer period after administration. This enables longer intervals between doses and, as a result, improved quality of personal life and an increased chance of successful treatment.
Lanolin or wool wax is a versatile ingredient and was used medicinally in ancient times. Lanolin is the secretion from sebum glands of sheep and is formed on the surface of their skin. However, the animals have to be treated with pesticides to protect them from parasites. The problem here is that these pesticides accumulate in the wool wax and can later lead to strong allergic reactions in users. This motivated IOI Oleo GmbH to develop a plant-based, synthetic alternative: et voila, SOFTISAN® 649 has since enriched our portfolio and has, among other things, made a name for itself as a lanolin substitute in the pharmaceutical industry.
An infusion can save lives and is used as a basic therapy in all areas of health care. The therapy, however, is complex and error-prone. Just as the patient relies on the correct diagnosis by the doctor and the proper execution by the specialist staff, so must the doctor and specialist staff rely on the quality of the infusions. With the MIGLYOL® product portfolio, the Pharma business unit of IOI Oleo GmbH offers high-quality carriers for injectables (infusions and injections).
In the early 2000s, the team of the IOI Oleo GmbH Pharma Business Unit asked themselves: Why do the principles and guidelines for active ingredients not also apply to excipients? As a result, the production site in Witten was GMP-certified, making IOI Oleo GmbH one of the first manufacturers of excipients to be GMP-certified. The certificate was recently confirmed again.
Medical applications and research have recently put cannabis in the spotlight and fueled a boom in demand. We now speak of a "green rush" - but what exactly triggered this demand? It is worth taking a closer look.